drugset / Trial / NCT01357837

Assessment of GRT6005 in Painful Osteoarthritis of the Knee

NCT01357837

Phase 2 Completed 207 enrolled Tris Pharma, Inc. Forest Laboratories · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the trial is to determine whether GRT6005 is effective in patients with pain due to osteoarthritis of the knee.

Timeline

Start
2011-05
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule 75 ug Oral
Subject Cebranopadol Small molecule 200 ug Oral
Subject Cebranopadol Small molecule 400 ug Oral

Indications